JP2010511397A - 血清タンパク質と結合可能なペプチド - Google Patents

血清タンパク質と結合可能なペプチド Download PDF

Info

Publication number
JP2010511397A
JP2010511397A JP2009539745A JP2009539745A JP2010511397A JP 2010511397 A JP2010511397 A JP 2010511397A JP 2009539745 A JP2009539745 A JP 2009539745A JP 2009539745 A JP2009539745 A JP 2009539745A JP 2010511397 A JP2010511397 A JP 2010511397A
Authority
JP
Japan
Prior art keywords
amino acid
sequence
acid sequence
sequences
immunoglobulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009539745A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010511397A5 (https=
Inventor
アディ ピエレット レヴェツ，ヒルデ
アレクサンドル コルクマン，ヨースト
レネラス ヤコブ マシュー ホーゲンブーム，ヘンドリック
ヴェルヘーセン，ピーター
スターレンズ，ステファニー
Original Assignee
アブリンクス エン．ヴェー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アブリンクス エン．ヴェー． filed Critical アブリンクス エン．ヴェー．
Publication of JP2010511397A publication Critical patent/JP2010511397A/ja
Publication of JP2010511397A5 publication Critical patent/JP2010511397A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2009539745A 2006-12-05 2007-12-05 血清タンパク質と結合可能なペプチド Withdrawn JP2010511397A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87292306P 2006-12-05 2006-12-05
PCT/EP2007/063348 WO2008068280A1 (en) 2006-12-05 2007-12-05 Peptides capable of binding to serum proteins

Publications (2)

Publication Number Publication Date
JP2010511397A true JP2010511397A (ja) 2010-04-15
JP2010511397A5 JP2010511397A5 (https=) 2010-12-16

Family

ID=39272498

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009539745A Withdrawn JP2010511397A (ja) 2006-12-05 2007-12-05 血清タンパク質と結合可能なペプチド

Country Status (7)

Country Link
US (1) US20080267949A1 (https=)
EP (1) EP2097449A1 (https=)
JP (1) JP2010511397A (https=)
CN (1) CN101611056A (https=)
AU (1) AU2007328900A1 (https=)
CA (1) CA2671581A1 (https=)
WO (1) WO2008068280A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101551306B1 (ko) 2015-03-23 2015-09-09 아주대학교산학협력단 뉴로필린1 특이적 결합 펩타이드 및 이 펩타이드가 융합된 융합 단백질, 및 이의 용도

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
US8603824B2 (en) 2004-07-26 2013-12-10 Pfenex, Inc. Process for improved protein expression by strain engineering
US9512236B2 (en) 2006-12-19 2016-12-06 Ablynx N.V. Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
JP5444553B2 (ja) 2007-04-27 2014-03-19 フェネックス インコーポレイテッド 微生物宿主を迅速にスクリーニングして、異種タンパク質発現の収率および／または質が改善されている特定の株を同定する方法
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
EP2220120A2 (en) * 2007-11-27 2010-08-25 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
EP2268668A1 (en) 2008-04-17 2011-01-05 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
NZ589036A (en) 2008-05-16 2012-07-27 Ablynx Nv AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
AU2009254501B2 (en) 2008-06-05 2014-07-31 Ablynx N.V. Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
US8444976B2 (en) 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
NZ595461A (en) 2009-04-10 2013-01-25 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
WO2010141329A1 (en) * 2009-06-01 2010-12-09 Medimmune, Llc Molecules with extended half-lives and uses thereof
ES2643034T3 (es) 2009-06-05 2017-11-21 Ablynx N.V. Construcciones de Nanobody contra el virus respiratorio sincicial humano (VRSH) trivalentes para la prevención y/o el tratamiento de infecciones de las vías respiratorias
WO2011064382A1 (en) 2009-11-30 2011-06-03 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
WO2011083141A2 (en) 2010-01-08 2011-07-14 Ablynx Nv Method for generation of immunoglobulin sequences by using lipoprotein particles
CN102781959A (zh) 2010-02-05 2012-11-14 埃博灵克斯股份有限公司 能够结合血清白蛋白的肽和包含所述肽的化合物、构建体和多肽
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
CN105153313A (zh) 2010-02-16 2015-12-16 诺沃—诺迪斯克有限公司 因子viii融合蛋白
UY33253A (es) 2010-03-03 2011-09-30 Boehringer Ingelheim Int Polipéptidos de unión a a-beta
US8937164B2 (en) 2010-03-26 2015-01-20 Ablynx N.V. Biological materials related to CXCR7
EP2563814A1 (en) 2010-04-30 2013-03-06 Ablynx N.V. Amino acid sequences of nanobodies directed against p19 subunit of the heterodimeric cytokine il-23
CN102906118B (zh) 2010-05-20 2017-07-28 埃博灵克斯股份有限公司 与her3相关的生物材料
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
CN103917560B (zh) 2011-03-28 2017-05-24 埃博灵克斯股份有限公司 双特异性抗‑cxcr7免疫球蛋白单可变结构域
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
WO2012163887A1 (en) 2011-05-27 2012-12-06 Ablynx Nv Inhibition of bone resorption with rankl binding peptides
EP2944653A1 (en) 2011-06-23 2015-11-18 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
IN2014CN00437A (https=) 2011-06-23 2015-04-03 Ablynx Nv
DK2723769T4 (da) * 2011-06-23 2022-09-05 Ablynx Nv Teknikker til at forudsige, påvise og reducere uspecifik proteininterferens i assays, som involverer variable immunglobulin-enkeltdomæner
DK2974737T3 (da) 2011-06-23 2026-01-19 Ablynx Nv Fremgangsmåder til forudsigelse, påvisning og reduktion af en specifik proteininterferens i assays, der involverer variable immunglobulin-enkeltdomæner
US10138302B2 (en) 2011-09-23 2018-11-27 Ablynx N.V. Methods for treating rheumatoid arthritis by administering interleukin-6 receptor antibodies
CN103889451B (zh) 2011-09-30 2016-06-29 埃博灵克斯股份有限公司 与C-Met相关的生物物质
AU2013226340B2 (en) 2012-02-27 2017-06-22 Ablynx N.V. CX3CR1-binding polypeptides
NL1040254C2 (en) 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
TWI707038B (zh) 2013-08-05 2020-10-11 美商扭轉生物科技有限公司 重新合成之基因庫
PL3248986T3 (pl) 2014-05-16 2022-05-16 Ablynx Nv Domeny zmienne immunoglobuliny
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
DE102014217793A1 (de) * 2014-09-05 2016-03-10 Jörg Labahn Fusionsprotein und Aufreinigungsverfahren
WO2016126882A1 (en) 2015-02-04 2016-08-11 Twist Bioscience Corporation Methods and devices for de novo oligonucleic acid assembly
US10273305B2 (en) 2015-04-02 2019-04-30 Ablynx N.V. Bispecific CXCR4-CD4 polypeptides with potent anti-HIV activity
US9981239B2 (en) 2015-04-21 2018-05-29 Twist Bioscience Corporation Devices and methods for oligonucleic acid library synthesis
CA3155409A1 (en) 2015-05-13 2016-11-17 Ablynx N.V. T cell recruiting polypeptides based on cd3 reactivity
PT3294768T (pt) 2015-05-13 2019-11-05 Ablynx Nv Polipétidos de recrutamento de células t com base na reatividade do tcr alfa/beta
KR20180050411A (ko) 2015-09-18 2018-05-14 트위스트 바이오사이언스 코포레이션 올리고핵산 변이체 라이브러리 및 그의 합성
KR102794025B1 (ko) 2015-09-22 2025-04-09 트위스트 바이오사이언스 코포레이션 핵산 합성을 위한 가요성 기판
NO2768984T3 (https=) 2015-11-12 2018-06-09
CR20180279A (es) 2015-11-18 2018-08-24 Merck Sharp & Dohme Enlazadores de ctla4
MA43260A (fr) 2015-11-18 2018-09-26 Merck Sharp & Dohme Liants pd1 et/ou lag3
WO2017089618A1 (en) 2015-11-27 2017-06-01 Ablynx Nv Polypeptides inhibiting cd40l
KR102802241B1 (ko) 2015-12-04 2025-05-07 베링거 인겔하임 인터내셔날 게엠베하 종양 세포에서 wnt 신호 전달을 길항하는 바이파라토픽 폴리펩타이드
WO2017202776A1 (en) 2016-05-23 2017-11-30 Luxembourg Institute Of Health (Lih) Multifunctional heteromultimeric constructs.
WO2018007442A1 (en) 2016-07-06 2018-01-11 Ablynx N.V. Treatment of il-6r related diseases
CN106282214A (zh) * 2016-08-03 2017-01-04 康众（北京）生物科技有限公司 一种快速获得纳米抗体的方法及其应用
WO2018029182A1 (en) 2016-08-08 2018-02-15 Ablynx N.V. Il-6r single variable domain antibodies for treatment of il-6r related diseases
US11098113B2 (en) 2016-09-15 2021-08-24 Vib Vzw Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
US10417457B2 (en) 2016-09-21 2019-09-17 Twist Bioscience Corporation Nucleic acid based data storage
CA3043515A1 (en) 2016-11-16 2018-05-24 Ablynx Nv T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta
CN110892485B (zh) 2017-02-22 2024-03-22 特韦斯特生物科学公司 基于核酸的数据存储
PL3630816T3 (pl) 2017-05-31 2024-08-05 Boehringer Ingelheim International Gmbh Polipeptydy antagonizujące sygnalizację wnt w komórkach nowotworowych
BR112019025097A2 (pt) 2017-06-02 2020-07-28 Merck Patent Gmbh imunoglobulinas de ligação a mmp13
TW202428621A (zh) 2017-06-02 2024-07-16 德商麥克專利有限公司 與ａｄａｍｔｓ５、ｍｍｐ１３及聚集蛋白聚醣結合的多肽
EP3630818A1 (en) 2017-06-02 2020-04-08 Ablynx NV Aggrecan binding immunoglobulins
IL270908B1 (en) 2017-06-02 2026-04-01 Merck Patent Gmbh ADAMTS-binding immunoglobulins
WO2018231864A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
US10696965B2 (en) 2017-06-12 2020-06-30 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
CN111566125A (zh) 2017-09-11 2020-08-21 特韦斯特生物科学公司 Gpcr结合蛋白及其合成
CN111565834B (zh) 2017-10-20 2022-08-26 特韦斯特生物科学公司 用于多核苷酸合成的加热的纳米孔
KR102804057B1 (ko) 2018-01-04 2025-05-07 트위스트 바이오사이언스 코포레이션 Dna 기반 디지털 정보 저장
CA3100739A1 (en) 2018-05-18 2019-11-21 Twist Bioscience Corporation Polynucleotides, reagents, and methods for nucleic acid hybridization
GB201818460D0 (en) * 2018-11-13 2018-12-26 Crescendo Biologics Ltd Single domain antibodies that bind human serum albumin
US12357959B2 (en) 2018-12-26 2025-07-15 Twist Bioscience Corporation Highly accurate de novo polynucleotide synthesis
CN113766930B (zh) 2019-02-26 2025-07-22 特韦斯特生物科学公司 Glp1受体的变异核酸文库
CA3131691A1 (en) 2019-02-26 2020-09-03 Twist Bioscience Corporation Variant nucleic acid libraries for antibody optimization
CN109942704B (zh) * 2019-04-12 2023-01-20 深圳普瑞金生物药业股份有限公司 Hsa单域抗体、核酸及试剂盒
CN113840835B (zh) * 2019-05-15 2024-06-25 克雷森多生物制剂有限公司 结合分子
AU2020298294A1 (en) 2019-06-21 2022-02-17 Twist Bioscience Corporation Barcode-based nucleic acid sequence assembly
WO2021061842A1 (en) 2019-09-23 2021-04-01 Twist Bioscience Corporation Variant nucleic acid libraries for single domain antibodies
JP2022548309A (ja) * 2019-09-23 2022-11-17 ツイスト バイオサイエンス コーポレーション Ｃｒｔｈ２のバリアント核酸ライブラリー
IL293670A (en) 2019-12-09 2022-08-01 Twist Bioscience Corp Variable nucleic acid libraries for adenosine receptors
CA3209052A1 (en) 2021-02-19 2022-08-25 Rafael Cristian CASELLAS Single domain antibodies that neutralize sars-cov-2
EP4314075A4 (en) 2021-03-24 2025-04-09 Twist Bioscience Corporation VARIANT NUCLEIC ACID BANKS FOR CD3
AR131494A1 (es) 2022-12-23 2025-03-26 Ablynx Nv Vehículos de conjugación a base de proteína
KR20260028051A (ko) 2023-06-22 2026-03-03 아블린쓰 엔.브이. 사이토카인의 수용체-활성을 조절하기 위한 키메라 단백질
TW202543670A (zh) 2023-12-22 2025-11-16 比利時商艾伯霖克斯公司 用於核內投予之基於蛋白質的接合載劑
US20250236673A1 (en) 2023-12-22 2025-07-24 Ablynx N.V. Protein-based carriers for site-specific amine conjugation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU701578B2 (en) * 1992-08-21 1999-02-04 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
AU1821397A (en) * 1995-12-21 1997-11-07 Scripps Research Institute, The Targeted therapeutic or diagnostic agents and methods of making and using same
EP1456410A2 (en) * 2001-12-11 2004-09-15 AlgoNomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
WO2003055527A2 (en) * 2002-01-03 2003-07-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Immunoconjugates useful for treatment of tumours
CA2505316C (en) * 2002-11-08 2014-08-05 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
WO2005044858A1 (en) * 2003-11-07 2005-05-19 Ablynx N.V. Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
AU2005325801A1 (en) * 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
US20070269422A1 (en) * 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
EP2268668A1 (en) * 2008-04-17 2011-01-05 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
US20110243954A1 (en) * 2008-04-17 2011-10-06 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101551306B1 (ko) 2015-03-23 2015-09-09 아주대학교산학협력단 뉴로필린1 특이적 결합 펩타이드 및 이 펩타이드가 융합된 융합 단백질, 및 이의 용도
WO2016153276A1 (ko) * 2015-03-23 2016-09-29 아주대학교산학협력단 뉴로필린1 특이적 결합 펩타이드 및 이 펩타이드가 융합된 융합 단백질, 및 이의 용도
US10400022B2 (en) 2015-03-23 2019-09-03 Ajou University Industry-Academic Cooperation Foundation Neuropilin-1 specific binding peptide, fusion protein fused with same, and use thereof

Also Published As

Publication number Publication date
AU2007328900A1 (en) 2008-06-12
WO2008068280A1 (en) 2008-06-12
US20080267949A1 (en) 2008-10-30
EP2097449A1 (en) 2009-09-09
CA2671581A1 (en) 2008-06-12
CN101611056A (zh) 2009-12-23

Similar Documents

Publication Publication Date Title
JP2010511397A (ja) 血清タンパク質と結合可能なペプチド
JP7093380B2 (ja) Ｉｌ－１７ａ、ｉｌ－１７ｆおよび／またはｉｌ１７－ａ／ｆに対するアミノ酸配列および前記アミノ酸配列を含むポリペプチド
JP5240870B2 (ja) 改善した免疫グロブリン配列を提供する方法
CN105061593B (zh) 改良的抗血清清蛋白结合变体
US10618964B2 (en) Nanobody against IL-6R
AU2011254559B2 (en) Improved anti-serum albumin binding variants
CN108473561B (zh) 抑制cd40l的多肽
CN102405233B (zh) 改良的抗血清清蛋白结合变体
JP2013518853A (ja) 血清アルブミンと結合することが可能なペプチド並びにこれを含む化合物、構築物及びポリペプチド
JP2011516603A (ja) 血清タンパク質と結合することが可能なペプチド、並びにこれを含む化合物、構築物及びポリペプチド
CA2705890A1 (en) Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
CN101589057A (zh) 以条件性方式结合于需要的分子的氨基酸序列
KR20230053002A (ko) 개선된 면역글로불린 가변 도메인

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101022

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101022

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111012

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20120912